logo
Share SHARE
FONT-SIZE Plus   Neg

Pfizer Unit Reaches Patent Litigation With Intelliject, Sanofi-Aventis

Mylan Inc. (MYL) and Pfizer Inc. (PFE) Thursday announced that Meridian Medical Technologies, a Pfizer subsidiary, has agreed with Intelliject and Sanofi-Aventis to resolve pending patent litigation related to Intelliject's new drug application for its epinephrine auto-injector known as e-cue.

E-cue will be manufactured and marketed by Sanofi-Aventis. Meridian manufactures EpiPen Auto-Injector and Mylan Specialty markets and distributes the product in the United States.

As per the settlement, Intelliject and Sanofi-Aventis may launch e-cue no earlier than November 15, 2012, subject to receipt of final approval from the U.S. Food and Drug Administration.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Online travel agency Priceline Group, Inc. on Wednesday reported an increase in profit for the first quarter from last year on double-digit revenue growth amid higher travel and room night bookings. Both adjusted earnings per share and quarterly revenues topped analysts' expectations. However, the company provided financial outlook for the second quarter below analysts' estimates. Time Warner Inc. (TWX) reported a profit for its first quarter ended March 31, 2016 that increased about 25 percent from the prior year. Revenues increased 3% and adjusted operating income grew 11% due to strong growth across all its operating divisions. It reaffirmed its 2016 adjusted earnings per share outlook. German telecom giant Deutsche Telekom AG reported Wednesday that its first-quarter net profit quadrupled on hefty stake sale gain. Revenues also increased on US strength, while domestic revenues were weak.
comments powered by Disqus
Follow RTT